Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis
Authors' conclusion
As compared with a standard DAPT, a 1-3-month DAPT regimen followed by P2Y12 inhibitor monotherapy reduced bleeding complications after C-PCI without increasing the risk of ischaemic events.
Study context
- Population
- Patients undergoing complex PCI (C-PCI)
- Participants
- 34,615 patients5 RCTs
- Comparison
- 1-3-month dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy vs standard DAPT
- Outcome
- Co-primary bleeding and ischaemic outcomes (defined per trial)
- Follow-up
- 12 months after randomization
Methodological detailscollaborative, random-effects models
- Collaborative
- Random-effects models
Pooled result
As reported in the abstract
Co-primary bleeding and ischaemic outcomes, by PCI complexity · 12 months
1-3-month DAPT vs Standard DAPTHazard ratio (95% CI)
Bleeding, C-PCI
0.66(0.44–0.98)
Bleeding, non-C-PCI
0.60(0.45–0.79)
Primary ischaemic endpoint, C-PCI
0.69(0.48–1.00)
Primary ischaemic endpoint, non-C-PCI
1.04(0.84–1.30)
Original publication
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. Published 23 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →